A New Genetic Laboratory for non-invasive prenatal diagnosis (ANGELab)

DropDisk to perform an automated digital droplet PCR for non-invasive prenatal diagnostic

This EU-FP7 project will develop a family of in vitro diagnostic systems that will transfer for the first time novel non-invasive prenatal diagnostic (NIPD) methods in tube to a lab-on-a-chip format. This family will consist of three research systems chosen to cover all prenatal diagnosis models.

ANGELab1: This system will use a lab-on-a-chip to extract fetal DNA from the mother´s plasma based on differences in methylated pattern between fetus and mother and captured by specific magnetophoresis, plus qPCR for monogenic diseases with a known mutation for: Spinal Muscular Atrophy, Cystic Fibrosis (CF), and X-linked disorders. It will be used only for high risk population.
ANGELab2: It will use a lab-on-a-chip to carry out immunoprecipitation (MeDIP) for fetal DNA extraction from mother´s blood and real time polymerase chain reaction (qPCR) for Aneuploidies of chromosomes 13, 18, 21, X and Y. It will be used for population screening purposes.
ANGELab3: This system will use the DNA sample provided from ANGELab1 or ANGELab2 and it will carry out digital PCR on a lab-on-a-chip to detect: multiple mutations CF, b-thalassemia and achondroplasia. I will be used for population screening purposes.

All systems can manage 8 samples at a time. They can be modularly assembled to themselves, offering a system adaptable to different throughput needs. The consortium will also develop and integrate a lab-on-a-chip pilot production line (LPPL) that will provide a sustainable and economic lab-on-a-chip manufacturing. Materials, processes, and their life cycle will be considered. The environmental assessment will be carried out following ISO 14044. Quality control tools will be integrated along the entire production chain of lab-on-a-chip systems. The LPPL is envisioned to serve as platform for the manufacture of any polymer based lab-on-a-chip systems.

back to overview

PROJECT FOOTNOTE:

Sponsor: EU
Funding Number: 317635
Duration: 01.10.2012 to 31.03.2017
Cooperation Partner: Ikerlan (SP), Hahn-Schickard (DE), AdemTech SA (FR), OSAKIDETZA/Basque Health Service (SP), Rioja Salud Foundation (SP), Wrocław University of Technology (PL), Cyprus Institute of Neurology and Genetics (CY), NIPD Genetics Ltd (CY), DNA Data (SP), Biopharma Technology Ltd (UK), EVGroup (AU), Fundación Gaiker (SP), BioDonostia (SP), CAN GmbH (GE), POC MicroSolutions (DE)
Maturity Level: Research > Research pattern

Contact


Dr. Nadine Borst
Hahn-Schickard,
Freiburg
Phone: +49 761 203-73208
Nadine.Borst@Hahn-Schickard.de
Directions

More information